Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 400-414

**Original article:**

**Clinical prospects for dyslipidemia treatment in patients with arterial hypertension.**

**A.S. Ermolayeva, O.V. Dralova, M.L. Maximov**

I.M.Sechenov First Moscow State Medical University , Moscow, Russia

Corresponding author: M.L. Maximov

Date of submission: 12 October 2014 ; Date of Publication: 30 December 2014

**Abstract:**

**Background:** Epidemiological research data shows that the prevalence of arterial hypertension among the adult population in the developed countries varies from 20% to 40% and increases with age. Hypertension is found in over 50% of men and women aged over 60. In Russia the structure of mortality patterns shows about 56% due to cardiovascular disease.

**Methodology :** We conducted an open prospective study of the lipid-lowering and antihypertensive efficacy of combined antihypertensive therapy using angiotensin-converting enzyme inhibitor Fozinopril (Fozinotec, Ranbaxy Laboratories Limited, India), starter dose: 10 mg per day and thiazide-like diuretic Indapamide (Retapres, Ranbaxy Laboratories Limited, India), starter dose: 1.5 mg per day, combined with diet therapy or administration of Simvastatin (Simvor, Ranbaxy Laboratories L The data we obtained demonstrates that combined therapy for patients presenting with dyslipidemic hypertension using angiotensin-converting enzyme inhibitor and statin can have a maximum effect on cardiovascular prognosis.

**Results and conclusion:** In case of an equal antihypertensive effect, the combination of Fozinopril and Simvastatin was much more effective than Fozinopril therapy in terms of decreasing the risk of major cardiovascular complications. An enhancement of the clinical effect in case of combining angiotensin-converting enzyme inhibitor with statins occurs, most likely, not due to the synergy of their hypotensive or hypolipidemic effects, but to their mutually enhancing angioprotective action on dyslipidemic hypertension .imited, India), starter dose: 20 mg per day. diseases associated with atherosclerosis.